Clinical Study

Summary

In this prospective controlled cross over clinical trial, the investigators aim to evaluate the efficacy and safety of acetazolamide for the management of metabolic alkalosis inchildren with Bartter syndrome. Urine and blood electrolytes will be measured before and after acetazolamide treatment. The primary end point is a change in polyuria, hypokalemia,and metabolic alkalosis.

Study Name: Acetazolamide (AZ) for Management of Alkalosis in Bartter Syndrome
Status: Recruiting
Conditions: Bartter Syndrome
Interventions: Drug: Acetazolamide
Locations: Fateme Ghane Sharbaf, Mashhad, Iran, Islamic Republic of, Semnan University of Medical Sciences, Semnan, Iran, Islamic Republic of, Banafshe Dormansh, Tehran, Iran, Islamic Republic of, Simin Sadeghi, Zahedan, Iran, Islamic Republic of
Study link: https://ClinicalTrials.gov/show/NCT03847571

To search for other studies by topic, location, or status, go to our Clinical Studies page.

©2021 Primary Aldosteronism Foundation — All Rights Reserved

The Primary Aldosteronism Foundation is a registered 501(c)(3) public charity. Donations are tax deductible in the US.

©2021 Primary Aldosteronism Foundation

The Primary Aldosteronism Foundation is a registered 501(c)(3) public charity. Donations are tax deductible in the US.